摘要:
The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as opioid agonists.
摘要:
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and n are as defined in the specification. These compounds are useful as MC4 agonists.
摘要:
The present invention provides compounds of formula (I) wherein R1 to R6 and m are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases, autoimmune diseases, pain, and. in the treatment of infection by HIV and genetically related retroviruses.
摘要:
This invention relates to nicotinamide derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing, and the uses of such derivatives: wherein each substituent is defined herein.
摘要:
A process is provide for the preparation of compounds of formula (I) herein comprising reacting a compound of formula (III), (IV) or (V) wherein the variables are as defined in the specification. The reaction is conducted in the presence of −OR3 and a hydroxide trapping agent or in the case of compounds of formula (IV) reacting in the presence of an auxiliary base and a hydroxide trapping agent.
摘要翻译:一种制备式(I)化合物的方法,其包括使式(III),(IV)或(V)化合物与变量如说明书中所定义的反应。 反应在< - > OR 3和氢氧化物捕获剂的存在下进行,或在式(Ⅳ)化合物的情况下,在辅助碱和氢氧化物捕获剂的存在下反应。
摘要:
Compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is H and the other is N═C(NH2)2 or NHC(═NH)NH2, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.
摘要:
The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as opioid agonists.
摘要:
Compounds of formula (I): or a pharmaceutically acceptable salt thereof, or solvate of either entity, wherein R4 is a guanidinyl moiety and the other substituents are as defined in the text, are urokinase inhibitors.
摘要:
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and n are as defined in the specification. These compounds are useful as MC4 agonists.
摘要:
There is provided a compound of formula I: wherein X represents O or NR5 R4 represents H, halo, cyano, nitro, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13, NR16Y(O)R17, N[Y(O)R17]2, SOR18, SO2R19, C(O)AZ, lower alkyl, lower alkenyl, lower alkynyl, Het, alkylHet, aryl, alkylaryl (which latter seven groups are all optionally substituted with one or more substituents selected from halo, cyano, nitro, lower alkyl, halo(loweralkyl), OR6, OC(O)R7, C(O)R8, C(O)OR9, C(O)NR10R11, NR12R13 and SO2NR14R15) which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g., cGMP PDE5) is desired.
摘要翻译:提供式I化合物:其中X代表O或NR 5 R 4表示H,卤素,氰基,硝基,卤素(低级烷基),OR 6,OC(O)R 7,C (O)R 8,C(O)OR 9,C(O)NR 10 R 11,NR 12 R 13,NR 16 Y(O)R 17 >,N [Y(O)R 17] 2,SOR 18,SO 2 R 19,C(O)AZ,低级烷基,低级烯基,低级炔基,Het,烷基Het,芳基,烷基芳基 七个基团都可以被一个或多个选自卤素,氰基,硝基,低级烷基,卤代(低级烷基),OR 6,OC(O)R 7,C(O)R 8, C(O)OR 9,C(O)NR 10 R 11,NR 12 R 13和SO 2 NR 14 R 15),其可用于治疗和预防性治疗 需要抑制环鸟嘌呤3',5'-单磷酸磷酸二酯酶(例如cGMP PDE5)的医学病症。